It is expected to fill the gap in the Global neonatal HIE treatment field, as Wanbangde Pharmaceutical Holding Group's subsidiary WP103 clinical trial application has been accepted by the FDA.

① Currently, no Pharmaceutical product containing Huperzine A has been approved for the market in the USA, and there are no approved drugs globally for the treatment of neonatal HIE. ② Multiple preclinical studies have shown that Huperzine A has significant potential for treating neonatal HIE, with the hope of addressing the pathophysiological challenges of hypoxia-ischemia through a comprehensive mechanism of action.

cls.cnDec 17 22:51

TGA Annual Best Action Game Award! "Black Myth: Wukong" sets a new milestone for Chinese gaming.

① On December 13, China's first 3A game "Black Myth: Wukong" won TGA's "Game of the Year" award and the "Players' Voice Award"; ② The game, developed by Game Science, is inspired by "Journey to the West" and has received widespread praise for its graphics, combat system, and storytelling; ③ "Black Myth" was nominated for four awards at TGA and won the 2024 Golden Joystick Award for "Game of the Year" among other awards.

cls.cnDec 13 13:13

Tasly Pharmaceutical Group: Some products price reduction led to a decline in Q3 gross margin. All parties are actively promoting the trade with China Resources Sanjiu Medical & Pharmaceutical | Focus on earnings conference

① Affected by the overall low prosperity of the pharmacy industry, the company's pharmaceutical commerce sector saw a decline in revenue in the third quarter this year; the pharmaceutical industry sector's revenue grew year-on-year, but price reductions on some products led to a decrease in gross margin, and the company expects the gross margin to remain stable in the future. ② Regarding the equity trade matters between the company's major shareholder and china resources sanjiu medical & pharmaceutical, the company's general manager Cai Jinyong stated that the company and relevant parties are actively promoting various works for this transaction.

cls.cnNov 27 22:29

The first domestically produced ADC drug has been fully approved for marketing in China. Kelunbote takes the lead. | Quick announcement

① Sichuan Kelun Pharmaceutical's holding subsidiary Kelun Botai has received domestic approval for the marketing of Lukanasatuzumab. ② This drug is used for the treatment of unresectable locally advanced or metastatic breast cancer and is the first domestically produced ADC to receive full approval for marketing in the country. ③ Two additional new drug applications for Lukanasatuzumab have been accepted by the NMPA.

cls.cnNov 27 21:14

Is Guangxi Wuzhou Zhongheng Group planning to sell the controlling stake of Chongqing Lummy Pharmaceutical after years of consecutive losses? | Quick read announcement

①Guangxi Wuzhou Zhongheng Group intends to transfer the shares held directly in Chongqing Lummy Pharmaceutical through public solicitation, and the controlling shareholder and actual controller of the latter may change. ②The story of Guangxi Wuzhou Zhongheng Group's investment in Chongqing Lummy Pharmaceutical began in November 2019 and became a major shareholder of Chongqing Lummy Pharmaceutical in April of the following year, making Guangxi State-owned Assets Supervision and Administration Commission the actual controller of Chongqing Lummy Pharmaceutical since then. ③In recent years, Chongqing Lummy Pharmaceutical has been in a continuous loss-making state.

cls.cnNov 26 22:55

This Thursday marks the start of the "soul negotiation" for medical insurance. Which companies are likely to be selected?

According to the National Medical Insurance Administration, a press conference will be held at 10 a.m. on November 28 at the National Medical Insurance Administration to announce the adjustments to the national medical insurance pharmaceutical catalog for 2024 and answer questions from reporters. This means that the results of the national negotiation for medical insurance centralized purchasing in 2024 will be announced this Thursday.

Securities TimesNov 26 19:39